Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
Z., Dranse, H
The skeletal muscles, brain, and heart of the body all contain the amino acid L carnitine injections, which is crucial for turning body fat into energy
pH-temperature responsive hydrogel-mediated delivery of exendin-4 encapsulated chitosan nanospheres for sustained therapeutic efficacy in type 2 diabetes mellitus
Could Mounjaro or related drugs treat cannabis use disorder and other substance addictions